A Case of Cerebral Toxoplasmosis and Cryptococcosis Preferred Therapy Associated Adverse Drug Reactions in a Patient Newly Co-diagnosed with Acquired Immune Deficiency Syndrome

Curr Drug Saf. 2023;18(3):393-397. doi: 10.2174/1574886317666220707144418.

Abstract

Purpose: The simultaneous occurrence of cerebral toxoplasmosis and cryptococcosis is rare. The infections continue to be treated with sulfadiazine and amphotericin-B-based regimens (preferred therapy), respectively. Both these drugs are linked to some serious adverse drug reactions (ADRs). We report such a unique instance of both; the CNS co-infections and adverse drug reactions to the preferred therapy.

Case presentation: A 44-year-old Asian-Indian female was diagnosed with cerebral toxoplasmosis, impending cryptococcal meningoencephalitis, and acquired immune deficiency syndrome (AIDS). The preferred therapy of opportunistic CNS co-infections commenced. Within a week, she had an occurrence of fall in hemoglobin concentrations (11.3 g/dL to 5.6 g/dL; grade IV), reticulocytosis (1% to 3.2%), and indirect hyperbilirubinemia (0.5 mg/dL to 2.8 mg/dL; grade IV) after sulfadiazine administration. The drug was discontinued and the patient was treated with hematocrit transfusions. After amphotericin-B deoxycholate (AmBd) administration, the patient developed hypokalemia (serum potassium; 4.5 mmol/L to 2.7 mmol/L) and increased serum creatinine (1.0 to 2.2 mg/dL; stage-I) levels. Hence, AmBd was discontinued and potassium correction was given. The patient got diagnosed with sulfadiazine induced hemolytic anemia and AmBd induced acute renal failure. He was switched to alternative therapy regimens for the treatment of cerebral toxoplasmosis and cryptococcosis. Radiological investigations were followed up to confirm the clinical outcomes of alternative therapy. Complete recovery from the ADRs and opportunistic infections was observed.

Conclusion: The preferred therapy regimens for toxoplasmosis and cryptococcosis are accompanied by potential adverse drug reactions, thus continuous monitoring is vital, especially in the initial phases of therapy. Discontinuation of the treatment should be the preliminary intervention in the management. Having said that, alternative therapy regimens had an optimal clinical response in the present case.

Keywords: CNS co-infection; CSF; HIV/AIDS; adverse reactions; amphotericin-B-deoxycholate; sulfadiazine.

Publication types

  • Case Reports

MeSH terms

  • Acquired Immunodeficiency Syndrome* / chemically induced
  • Acquired Immunodeficiency Syndrome* / complications
  • Acquired Immunodeficiency Syndrome* / drug therapy
  • Adult
  • Amphotericin B / adverse effects
  • Antifungal Agents / adverse effects
  • Coinfection* / chemically induced
  • Coinfection* / complications
  • Coinfection* / drug therapy
  • Cryptococcosis* / complications
  • Cryptococcosis* / diagnosis
  • Cryptococcosis* / drug therapy
  • Drug-Related Side Effects and Adverse Reactions*
  • Female
  • Humans
  • Male
  • Potassium / therapeutic use
  • Sulfadiazine / adverse effects
  • Toxoplasmosis, Cerebral* / chemically induced
  • Toxoplasmosis, Cerebral* / diagnosis
  • Toxoplasmosis, Cerebral* / drug therapy

Substances

  • Amphotericin B
  • Antifungal Agents
  • Sulfadiazine
  • Potassium